Stocktoria
CervoMed Inc. CRVO
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2016-11-09
CervoMed Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.0M | $9.7M | $7.1M | $0 | — | — | — | — | — | — |
| R&D expense | $21.8M | $18.8M | $8.4M | $1.3M | $8.5M | $9.4M | $6.6M | $5.8M | $5.1M | $7.3M |
| Operating income | -$28.3M | -$18.2M | -$7.8M | -$3.5M | -$24.7M | -$16.0M | -$11.6M | -$19.0M | -$11.3M | -$18.4M |
| Interest expense | — | — | $0 | $587 | — | — | — | $3,000 | $100,000 | $37,000 |
| Income tax | $0 | — | — | $0 | -$443,893 | -$1.7M | $332,885 | -$437,289 | -$1.1M | -$364,796 |
| Net income | -$27.0M | -$16.3M | -$2.2M | -$5.8M | -$24.1M | -$14.2M | -$11.8M | -$18.4M | -$1.4M | -$18.0M |
| EPS (diluted) | — | — | — | $2038891.00 | $1946859.00 | $53831973.00 | $6706509.00 | $3242301.00 | $-29.11 | $-1.76 |
| Operating cash flow | -$23.4M | -$16.5M | -$7.4M | -$2.6M | -$14.5M | -$13.6M | -$9.9M | -$10.8M | -$12.3M | -$10.8M |
| Free cash flow | — | — | — | — | — | — | — | — | -$12.8M | -$10.8M |
| Cash & equivalents | $8.2M | $9.0M | $7.8M | $4.1M | $37.3M | $18.5M | $14.2M | $8.0M | $8.9M | $1.6M |
| Total assets | $22.9M | $43.1M | $10.0M | $4.2M | $37.8M | $27.7M | $24.1M | $18.2M | $26.1M | $17.5M |
| Total liabilities | $4.7M | $3.9M | $2.6M | $13.2M | $2.9M | $2.9M | $4.0M | $2.6M | $4.9M | $8.3M |
| Shareholders' equity | $18.2M | $39.2M | $7.4M | -$33.3M | $34.9M | $24.8M | $20.1M | $15.6M | $21.2M | $9.2M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -58.9% | +36.3% | — | — | — | — | — | — | — | — |
| EPS growth | — | — | — | +4.7% | -96.4% | +702.7% | +106.8% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.